Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 446

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction

Open access
Broch, Kaspar, Anstensrud, Anne Kristine, Woxholt, Sindre, Sharma, Kapil, Tøllefsen, Ingvild Maria, Bendz, Bjørn, Aakhus, Svend, Ueland, Thor, Amundsen, Brage Høyem, Damås, Jan Kristian, Berg, Erlend Sturle, Bjørkelund, Elisabeth, Bendz, Christina, Hopp, Einar, Kleveland, Ola, Stensæth, Knut Haakon, Opdahl, Anders, Kløw, Nils-Einar, Seljeflot, Ingebjørg, Andersen, Geir Øystein, Wiseth, Rune, Aukrust, Pål, Gullestad, Lars·2021·Journal of the American College of Cardiology

Abstract

BACKGROUND Prompt myocardial revascularization with percutaneous coronary intervention (PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation myocardial infarction (STEMI). However, as much as 50% of the loss of viable myocardium may be attributed to the reperfusion injury and the associated inflammatory response. OBJECTIVES This study sought to evaluate the effect of the interleukin-6 receptor inhibitor tocilizumab on myocardial salvage in acute STEMI. METHODS The ASSAIL-MI trial was a randomized, double-blind, placebo-controlled trial conducted at 3 high-volume PCI centers in Norway. Patients admitted with STEMI within 6 h of symptom onset were eligible. Consenting patients were randomized in a 1:1 fashion to promptly receive a single infusion of 280 mg tocilizumab or placebo. The primary endpoint was the myocardial salvage index as measured by magnetic resonance imaging after 3 to 7 days. RESULTS We randomized 101 patients to tocilizumab and 98 patients to placebo. The myocardial salvage index was larger in the tocilizumab group than in the placebo group (adjusted between-group difference 5.6 [95% confidence interval: 0.2 to 11.3] percentage points, p = 0.04). Microvascular obstruction was less extensive in the tocilizumab arm, but there was no significant difference in the final infarct size between the tocilizumab arm and the placebo arm (7.2% vs. 9.1% of myocardial volume, p = 0.08). Adverse events were evenly distributed across the treatment groups. CONCLUSIONS Tocilizumab increased myocardial salvage in patients with acute STEMI. (ASSessing the effect of Anti-IL-6 treatment in Myocardial Infarction [ASSAIL-MI]; NCT03004703).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2021.02.049

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 446

Metadata

Authors
Broch, K., Anstensrud, A. K., Woxholt, S., Sharma, K., Tøllefsen, I. M., Bendz, B., Aakhus, S., Ueland, T., Amundsen, B. H., Damås, J. K., Berg, E. S., Bjørkelund, E., Bendz, C., Hopp, E., Kleveland, O., Stensæth, K. H., Opdahl, A., Kløw, N.-E., Seljeflot, I., Andersen, G. Ø., Wiseth, R., Aukrust, P., & Gullestad, L.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2021-04
Volume
77
Issue
15
Pages
1845-1855
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3153495812
Cited by
446
References
25
FWCI
35.39
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. https://app.cochat.ai/papers/10.1016/j.jacc.2021.02.049
The paper
Broch, K., Anstensrud, A. K., Woxholt, S., Sharma, K., Tøllefsen, I. M., Bendz, B., Aakhus, S., Ueland, T., Amundsen, B. H., Damås, J. K., Berg, E. S., Bjørkelund, E., Bendz, C., Hopp, E., Kleveland, O., Stensæth, K. H., Opdahl, A., Kløw, N.-E., Seljeflot, I., . . . Gullestad, L. (2021). Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2021.02.049

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.